Beacon Biosignals is a pioneering company dedicated to transforming precision medicine for brain health. As the leading at-home EEG platform, Beacon supports the clinical development of innovative therapeutics for neurological, psychiatric, and sleep disorders. With its FDA 510(k)-cleared Dreem EEG headband and advanced AI algorithms, the company facilitates quantitative biomarker discovery and implementation. Beacon's extensive Clinico-EEG database, which includes EEG data from nearly 100,000 patients, along with its cloud-native analytics platform, enables large-scale retrospective and predictive studies. The company is committed to making brain monitoring accessible, interpretable, and actionable, ultimately changing the treatment landscape for disorders affecting brain physiology. Beacon promotes a flexible work environment with robust remote practices, while also offering in-person office hubs in Boston, New York, and Paris.